Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism.

Burgués S, Calderón MD

Human reproduction (Oxford, England)1 May 1997Cited by 71 (Europe PMC)

PMID9194651DOI10.1093/humrep/12.5.980PepBankPUB-09194651

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking hCG (human chorionic gonadotropin).

01HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotrophic hypogonadism, FSH with HCG rapidly increased testosterone, and all but one patient reached normal concentrations.
In plain wordsIn men with hypogonadotrophic hypogonadism, FSH with HCG increased testosterone to normal values in nearly all patients.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseTestosterone
Study
n = 60
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Patients who did not reach normal testosterone concentrations
1 patient
FSH with HCG during treatment
Source sentences
Summary
Testosterone concentrations increased rapidly during treatment and all but one patient reached normal values.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465101
02HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotrophic hypogonadism, testicular volume increased to almost 3-fold baseline during FSH with HCG treatment.
In plain wordsIn men with hypogonadotrophic hypogonadism, FSH with HCG increased testicular volume compared with baseline.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseTesticular volume
Study
n = 60
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Testicular volume relative to baseline
≈ 3 fold
FSH with HCG, sustained increase
Source sentences
Summary
Testicular volume showed a sustained increase reaching almost 3-fold its baseline value.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465102
03HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotrophic hypogonadism, 48 patients (80.0%) achieved positive sperm counts during FSH with HCG treatment.
In plain wordsIn men with hypogonadotrophic hypogonadism, FSH with HCG produced positive sperm counts in most patients.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreasePositive sperm count
Study
n = 60
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Patients with positive sperm count
48 patients (of 60)
end of treatment
Patients with positive sperm count
80%
end of treatment
Source sentences
Summary
At the end of treatment, 48 patients (80.0%) had achieved a positive sperm count.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465103
04HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialSafety outcome
In men receiving FSH with HCG, eleven patients reported adverse events, generally unrelated to treatment.
In plain wordsIn men receiving FSH with HCG, eleven reported adverse events, generally unrelated to treatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableAdverse events
Study
n = 60
Outcome group
Adverse events · Whole body
Measurements
Patients reporting adverse events
11 patients (of 60)
FSH with HCG
Source sentences
Summary
Eleven patients reported adverse events, generally not related to treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465106
05HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialSafety outcome
In men receiving FSH with HCG, three patients experienced gynaecomastia.
In plain wordsIn men receiving FSH with HCG, three developed enlarged breast tissue.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableGynaecomastia
Study
n = 60
Outcome group
Adverse events · Reproductive and sexual health
Measurements
Patients with gynaecomastia
3 patients (of 60)
FSH with HCG
Source sentences
Summary
Three patients experienced gynaecomastia.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465107
06HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialSafety outcome
In men receiving FSH with HCG, no local injection-site reactions occurred.
In plain wordsIn men receiving FSH with HCG, no injection-site reactions occurred.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableInjection-site reactions
Study
n = 60
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
No local reactions at injection site were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465108
07HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotrophic hypogonadism, maximum sperm concentration during FSH with HCG treatment was 24.5 +/- 8.1 x 10(6)/ml.
In plain wordsIn men with hypogonadotrophic hypogonadism, the highest sperm concentration during FSH with HCG treatment averaged 24.5 x 10(6)/ml.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableMaximum sperm concentration
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Maximum sperm concentration
24.5 x 10(6)/ml
mean during treatment, SEM 8.1
SEM of mean maximum sperm concentration
8.1 x 10(6)/ml
during FSH with HCG treatment, parent mean 24.5 x 10(6)/ml
Source sentences
Summary
The maximum sperm concentration during treatment was 24.5 +/- 8.1 x 10(6)/ml (mean +/- SEM).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465104
08HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotrophic hypogonadism, median time to spermatogenesis with FSH and HCG was 5 months.
In plain wordsIn men with hypogonadotrophic hypogonadism, sperm production began after a median of 5 months with FSH and HCG.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableTime to spermatogenesis
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Median time to induce spermatogenesis
5 months
FSH with HCG
Source sentences
Summary
The median time to induce spermatogenesis was 5 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of highly purified follicle stimulating hormone (FSH) associated with human chorionic gonadotrophin (HCG) was studied in 60 men with hypogonadotrophic hypogonadism.
Summary · context
All patients self-administered s.c. injections of FSH (150 IU x three/week) and HCG (2500 IU x two/week) for at least 6 months and underwent periodic assessments of testicular function.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0919465105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.